Medical College of Wisconsin
CTSIResearch InformaticsREDCap

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Clin Transl Radiat Oncol 2021 May;28:124-128

Date

05/14/2021

Pubmed ID

33981865

Pubmed Central ID

PMC8085778

DOI

10.1016/j.ctro.2021.04.002

Scopus ID

2-s2.0-85104326512 (requires institutional sign-in at Scopus site)   7 Citations

Abstract

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

Author List

Ryckman JM, Reames BN, Klute KA, Hall WA, Baine MJ, Abdel-Wahab M, Lin C

Author

William Adrian Hall MD Chair, Professor in the Radiation Oncology department at Medical College of Wisconsin